DVT - Deep Vein ThrombosisDVTNCT06732726
Padua Prediction Score for VTE Risk in Thoracic Surgery Patients
An observational study of DVT - Deep Vein Thrombosis and VTE (Venous Thromboembolism), run by Al-Nahrain University at 1 site in Iraq.
Trial summary
The goal of this observational study is to assess the predictive accuracy of the Padua Prediction Score (PPS) for venous thromboembolism (VTE) risk in thoracic surgery patients. The study aims to answer the following question: Does the PPS provide a more accurate prediction of VTE risk? Participants will: Have their… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- DVT - Deep Vein Thrombosis, VTE (Venous Thromboembolism)
- How many people
- 150 participants
- Where
- 1 siteIraq
- Study dates
- 20 Apr 2025to 15 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will focus on adult patients undergoing thoracic surgery at a single center in Iraq.
Who may be able to join
- Patients who have undergone preoperative Padua Prediction Score assessment.
- Inpatients with a hospital stay over 3 days
- Written informed consent obtained from patients or their legal guardians.
- Availability for postoperative follow-up to assess outcomes like LEVT development or related complications.
Who cannot join
- Preexisting LEVT or pulmonary embolism.
- Severe Coagulopathy: Patients with inherited or acquired bleeding disorders (e.g., hemophilia, advanced liver disease).
- receiving any anticoagulation therapy for any reason.
- patients who did not undergo a postoperative D-dimer test.
- Incomplete Data: missing essential clinical or laboratory data.
- Pregnancy: pregnant women or those within six weeks postpartum.
- Noncompliance: Patients unwilling or unable to adhere to study follow-up protocols.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Iraq1 site, 1 recruiting
- Recruiting
College of Medicine - Al-Nahrain University
Baghdad, Kadhimiya
Abdul-Ilah R. Khamis
Zahraa Bassam Alkhalidy, Student
About this study
Official title: Assessment of the Padua Prediction Score for Venous Thromboembolism Risk Stratification in Thoracic Surgery Patients: Insights From a Single-Center Cohort Study in Iraq
The goal of this observational study is to assess the predictive accuracy of the Padua Prediction Score (PPS) for venous thromboembolism (VTE) risk in thoracic surgery patients.
The study aims to answer the following question:
Does the PPS provide a more accurate prediction of VTE risk?
Participants will:
Have their VTE risk assessed using the PPS during their hospital admission.
Read the detailed description
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality, comprising conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE). Hospitalized patients are particularly vulnerable to VTE due to factors such as prolonged immobility, surgical procedures, and preexisting comorbidities.
To address this risk, tools like the Padua Prediction Score (PPS) have been developed. PPS is a validated scoring system that uses clinical and demographic criteria to categorize patients as high- or low-risk for VTE, allowing healthcare providers to tailor prophylactic measures accordingly. Although the Padua Prediction Score has been increasingly adopted in various healthcare settings, its applicability in Iraq remains understudied. There is limited local data on the prevalence of VTE, risk assessment practices and adherence to prophylaxis protocols, leaving a clear gap in the literature. This study aims to explore the utility and predictive accuracy of the Padua Prediction Score in the Iraqi healthcare context. By addressing this gap, the findings could help refine VTE prevention strategies, improve resource allocation, and ultimately reduce complications associated with this condition.
- Keywords
- Padua Prediction Score (PPS)
- Medical subject headings
- Venous Thrombosis, Venous Thromboembolism
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Venous Thromboembolism (VTE) Episodes in Patients
symptomatic or asymptomatic, confirmed by instrumental diagnostics.
Measured: In-Hospital Phase (average of 10 days through discharge); Post-Discharge Follow-Up: Day 7, Day 15, and Day 30
Padua Prediction Score
A total score that ranges from 0 to 20. 4 or higher indicates a significant likelihood of developing VTE.
Measured: Day 1 preoperative (one day prior to surgery)
Secondary outcomes (2)
Incidence of Symptomatic Pulmonary Embolism in Patients
symptomatic pulmonary embolism confirmed by perfusion isotope scanning or CT pulmonary angiography.
Measured: In-Hospital Phase (average of 10 days through discharge); Post-Discharge Follow-Up: Day 7, Day 15, and Day 30
Rate of Recurrent Deep Vein Thrombosis (DVT) in Patients
A new episode of deep vein thrombosis occurs after the initial diagnosis with clinical symptoms (such as leg pain, swelling, redness, or tenderness) and is confirmed through instrumental diagnostics (e.g., ultrasound, CT venography, MRI).
Measured: Post-Discharge Follow-Up: Day 7, Day 15, and Day 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2024
- Study start20 Apr 2025
- Primary completion1 Jul 2027 (estimated)
- Study completion15 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for DVT - Deep Vein ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Al-Nahrain University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Abdulillah R. Khamees, Al-Nahrain University
- Investigators
- Yaser aamer Eisa Alhaibi, Assistant professor, Study director, College Of Medicine - Nahrain University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06732726
- Sponsor's protocol ID
- UNCOMIRB20241210
- Other IDs
- 008
- Acronym
- DVT
- Status last verified
- Sep 2026
- First submitted
- 10 Dec 2024
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Al Yami MS, Silva MA, Donovan JL, Kanaan AO. Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis. J Thromb Thrombolysis. 2018 Jan;45(1):36-47. doi: 10.1007/s11239-017-1562-5.
PubMed 29043538Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010 Nov;8(11):2450-7. doi: 10.1111/j.1538-7836.2010.04044.x.
PubMed 20738765
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of the Padua Prediction Score for Venous Thromboembolism Risk Stratification in Thoracic Surgery Patients: Insights From a Single-Center Cohort Study in Iraq
- ClinicalTrials.gov ID
- NCT06732726
- Acronym / sponsor ID
- DVT / UNCOMIRB20241210
- Keywords
- Padua Prediction Score (PPS)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Al-Nahrain UniversityUniversity, hospital or other
- Study start
- 20 Apr 2025 (actual)
- Primary completion
- 1 Jul 2027 (estimated)
- Study completion
- 15 Jul 2027 (estimated)
- First posted
- 13 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to assess the predictive accuracy of the Padua Prediction Score (PPS) for venous thromboembolism (VTE) risk in thoracic surgery patients.
The study aims to answer the following question:
Does the PPS provide a more accurate prediction of VTE risk?
Participants will:
Have their VTE risk assessed using the PPS during their hospital admission.
Detailed description
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality, comprising conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE). Hospitalized patients are particularly vulnerable to VTE due to factors such as prolonged immobility, surgical procedures, and preexisting comorbidities.
To address this risk, tools like the Padua Prediction Score (PPS) have been developed. PPS is a validated scoring system that uses clinical and demographic criteria to categorize patients as high- or low-risk for VTE, allowing healthcare providers to tailor prophylactic measures accordingly. Although the Padua Prediction Score has been increasingly adopted in various healthcare settings, its applicability in Iraq remains understudied. There is limited local data on the prevalence of VTE, risk assessment practices and adherence to prophylaxis protocols, leaving a clear gap in the literature. This study aims to explore the utility and predictive accuracy of the Padua Prediction Score in the Iraqi healthcare context. By addressing this gap, the findings could help refine VTE prevention strategies, improve resource allocation, and ultimately reduce complications associated with this condition.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will focus on adult patients undergoing thoracic surgery at a single center in Iraq.
Key inclusion criteria (4 listed)
- Patients who have undergone preoperative Padua Prediction Score assessment.
- Inpatients with a hospital stay over 3 days
- Written informed consent obtained from patients or their legal guardians.
- Availability for postoperative follow-up to assess outcomes like LEVT development or related complications.
Key exclusion criteria (7 listed)
- Preexisting LEVT or pulmonary embolism.
- Severe Coagulopathy: Patients with inherited or acquired bleeding disorders (e.g., hemophilia, advanced liver disease).
- receiving any anticoagulation therapy for any reason.
- patients who did not undergo a postoperative D-dimer test.
- Incomplete Data: missing essential clinical or laboratory data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of Venous Thromboembolism (VTE) Episodes in Patients
Time frame: In-Hospital Phase (average of 10 days through discharge); Post-Discharge Follow-Up: Day 7, Day 15, and Day 30
symptomatic or asymptomatic, confirmed by instrumental diagnostics.
Padua Prediction Score
Time frame: Day 1 preoperative (one day prior to surgery)
A total score that ranges from 0 to 20. 4 or higher indicates a significant likelihood of developing VTE.
2 secondary outcomes
Incidence of Symptomatic Pulmonary Embolism in Patients
Time frame: In-Hospital Phase (average of 10 days through discharge); Post-Discharge Follow-Up: Day 7, Day 15, and Day 30
Rate of Recurrent Deep Vein Thrombosis (DVT) in Patients
Time frame: Post-Discharge Follow-Up: Day 7, Day 15, and Day 30
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
- Background: PubMed 29043538Al Yami MS, Silva MA, Donovan JL, Kanaan AO. Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis. J Thromb Thrombolysis. 2018 Jan;45(1):36-47. doi: 10.1007/s11239-017-1562-5.
- Results publication: PubMed 20738765Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010 Nov;8(11):2450-7. doi: 10.1111/j.1538-7836.2010.04044.x.
- Individual participant dataSharing planned: No
Related trials for DVT - Deep Vein Thrombosis
RecruitingObservational study
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature
RecruitingObservational study
Predictive Value of Modified Caprini Score and D-Dimer in Managing Lower Limb Venous Thrombosis in Cardiothoracic Patients
DVT - Deep Vein Thrombosis
Active, not recruiting
BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
Deep Vein Thrombosis, DVT
Recruiting
Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chronic Post-thrombotic Venous Ulcers
Vascular, DVT - Deep Vein Thrombosis
RecruitingObservational study
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yaser aamer Eisa Alhaibi, Assistant professor study director
College Of Medicine - Nahrain University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of DVT - Deep Vein Thrombosis and VTE (Venous Thromboembolism), run by Al-Nahrain University at 1 site in Iraq.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Abdul-Ilah R. Khamis (+9647838571013, allaabed987@ced.nahrainuniv.edu.iq), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Venous Thromboembolism (VTE) Episodes in Patients (time frame: In-Hospital Phase (average of 10 days through discharge); Post-Discharge Follow-Up: Day 7, Day 15, and Day 30). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06732726, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.